Sitemap
-
Contact
-
BioInvent has been listed on the NASDAQ OMX Stockholm since 2001. Our projects are based around a competitive and in substance patented antibody development platform. The scope and strength of this platform is also utilised by high-profile partners.
Home
About BioInvent
Products
Partners
Science
Investors
Media Centre
Strategy
Management Team
Board of Directors
Corporate Citizenship
Careers
Pipeline
Oncology
Atherosclerosis
Thrombosis
Clinical Trials
Product Alliances
Technology Partnerships
Monoclonal Antibodies
n-CoDeR®
Biopanning
Manufacturing
Biologic and Preclinical Expertise
The Share
Financial Reports
Press Releases
Presentations
Investor Information
Corporate Governance
Investor Contact
Subscription Service
Press Releases
Downloads
Events
The Share
»
Share Price Information
Five Year Summary
Subscription Service
Financial Reports
»
Annual Reports and Interim Reports
Prospectuses
Press Releases
Presentations
Investor Information
»
Financial Calendar
Analysts
Owners
Corporate Governance
»
Articles of Association
General Meetings
Board of Directors and Auditors
Committees
Management
Principles of Remuneration
Incentive Programme
Corporate Governance Reports
Investor Contact
Subscription Service
Subscription Service
Please fill in the form below to subscribe to share price information.
Please alert me if the share price goes
above
SEK
or below
SEK
Please alert me if the share price changes by
%
Please send me the closing share price
Daily
Weekly
E-mail
BioInvent International
SE-223 70 Lund, Sweden Visiting: Sölvegatan 41, Lund, Sweden Tel: +46 (0)46-286 85 50 E-mail:
info@bioinvent.com